CommercialBilling CodesMedium impact
07.03.26b, Tumor Treating Fields
Independence Blue Cross·Oncology, Neurosurgery, Neurology +1 more·Medical Policy
Effective date
Jan 1, 2026
We identified it
Jul 23, 2026
Summary
Independence Blue Cross reissued Policy 07.03.26b on Tumor Treating Fields (TTFields) for glioblastoma treatment, adding CPT code 1025T (dosimetry and delivery simulation) as medically necessary effective 01/01/2026. The policy covers TTFields for newly diagnosed glioblastoma with adjuvant temozolomide and recurrent glioblastoma as monotherapy in adult patients meeting specific clinical criteria. Billing teams must ensure claims for TTFields therapy include proper documentation and use the correct HCPCS code E0766 for device reimbursement.
Action Required
By 01/01/2026: Billing team must update billing software and claim submission protocols to recognize CPT 1025T as a covered service for TTFields therapy. Ensure claims for E0766 (TTFields device) include proper ICD-10 diagnosis codes (C71.0-C71.9) and documentation of patient eligibility: age 22+, histologically confirmed WHO Grade IV glioblastoma, supratentorial tumor location, Karnofsky Performance Score >60, completion of standard therapy, and willingness to use device 18+ hours daily. For newly diagnosed glioblastoma claims, verify adjuvant temozolomide is prescribed; for recurrent glioblastoma, verify monotherapy status. Do NOT separately reimburse A4555 replacement electrodes—bundle with E0766 monthly payment. Update encounter forms and prior authorization templates to capture required clinical documentation. Remove or deny claims for TTFields in patients with implanted pacemakers, defibrillators, programmable shunts, deep brain stimulators, or clinical contraindications. All other TTFields uses (mesothelioma, NSCLC, pancreatic cancer) remain experimental/investigational and must be denied. Failure to apply these requirements will result in claim denials.